These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1904285)

  • 21. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.
    Fluckiger AC; Rossi JF; Bussel A; Bryon P; Banchereau J; Defrance T
    Blood; 1992 Dec; 80(12):3173-81. PubMed ID: 1281692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD23 antigen regulation and signaling in chronic lymphocytic leukemia.
    Fournier S; Delespesse G; Rubio M; Biron G; Sarfati M
    J Clin Invest; 1992 Apr; 89(4):1312-21. PubMed ID: 1532590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
    Elsässer D; Valerius T; Repp R; Weiner GJ; Deo Y; Kalden JR; van de Winkel JG; Stevenson GT; Glennie MJ; Gramatzki M
    Blood; 1996 May; 87(9):3803-12. PubMed ID: 8611706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
    Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
    Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.
    Suresh K; Fraser G; Scheid E; Leber B; Gauldie J; Foley R
    Leuk Lymphoma; 2006 Feb; 47(2):297-306. PubMed ID: 16321861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-dependent cell-mediated cytotoxicity against human eye muscle cells and orbital fibroblasts in Graves' ophthalmopathy--roles of class II MHC antigen expression and gamma-interferon action of effector and target cells.
    Hiromatsu Y; Fukazawa H; How J; Wall JR
    Clin Exp Immunol; 1987 Dec; 70(3):593-603. PubMed ID: 3124997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.
    Buschle M; Campana D; Carding SR; Richard C; Hoffbrand AV; Brenner MK
    J Exp Med; 1993 Jan; 177(1):213-8. PubMed ID: 7678114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells.
    Erbe DV; Collins JE; Shen L; Graziano RF; Fanger MW
    Mol Immunol; 1990 Jan; 27(1):57-67. PubMed ID: 2138246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
    Loubeau M; Ahmad A; Toma E; Menezes J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon.
    Akiyama Y; Lubeck MD; Steplewski Z; Koprowski H
    Cancer Res; 1984 Nov; 44(11):5127-31. PubMed ID: 6435864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
    Notter M; Ludwig WD; Bremer S; Thiel E
    Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal Lym-1 antibody-targeted lysis of B lymphoma cells by neutrophils. Evidence for two mechanisms of FcgammaRII-dependent cytolysis.
    Ottonello L; Epstein AL; Mancini M; Amelotti M; Dapino P; Dallegri F
    J Leukoc Biol; 2000 Nov; 68(5):662-8. PubMed ID: 11073105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL.
    Czuczman MS; Class K; Scheinberg DA
    Leukemia; 1993 Jul; 7(7):1020-5. PubMed ID: 7686603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.